Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Plus Therapeutics's Rhenium (186Re) Obisbemeda?
Rhenium (186Re) Obisbemeda is a small molecule commercialized by Plus Therapeutics, with a leading Phase II program in Recurrent Glioblastoma...
Data Insights
Risk adjusted net present value: What is the current valuation of Plus Therapeutics's Rhenium (186Re) Obisbemeda?
Rhenium (186Re) Obisbemeda is a small molecule commercialized by Plus Therapeutics, with a leading Phase II program in Leptomeningeal Disease...